Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Search Results

Title:
G3004 SOLO1 A Phase III, Randomized, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy (D0818C00001)
Protocol Number:
NCTNIG3004
Phase:
Phase III
Physician:
Deborah Armstrong
Purpose:
- To determine the efficacy of olaparib maintenance monotherapy compared toplacebo in BRCA mutated high risk advanced ovarian cancer patients who are inclinical complete response or partial response following first line platinum basedchemotherapy- To compare the effects of olaparib maintenance monotherapy compared to placeboon quality of life
Eligibility:
- BRCA mutation- Completed 6-9 cycles of platinum based chemotherapy after initial diagnosis- Stage III or IV at diagnosis- No prior parp inhibitors- Good lab values and performance status- Must start within 8 wks of last chemotherapy treatment
Treatment:
Women are randomized to receive either olaparib or placebo. This is an oral drug that is taken twice daily. Each cycle is 28 days. You will have to come in as an outpatient once a month to receive a new supply. The visits are weekly during the first cycle. Treatment continues for up to 2 years.
Population:
Adult
Last Update
09/30/2014 04:03 AM
 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

 

Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer